Verapamil for preventing adverse cardiovascular events

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1385, 2003-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ephedra: risk of adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Lipid Management Strategies for the Prevention of Adverse Cardiovascular Events

By  

Heart Drug, Vol. 2, Iss. 4, 2002-11 ,pp. : 159-161

Karger

Access to resources Recommend Favorite

Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Common mutations and polymorphisms predicting adverse cardiovascular events: current view

By Visvikis-Siest Sophie   Stathopoulou Maria G   Ndiaye Ndeye Coumba  

Pharmacogenomics, Vol. 13, Iss. 16, 2012-12 ,pp. : 1875-1878

Future Medicine

Access to resources Recommend Favorite

Preventing cardiovascular disease in diabetes

By Harvey John N.  

Clinical Medicine, Vol. 4, Iss. 4, 2004-07 ,pp. : 311-314

Royal College Of Physicians

Access to resources Recommend Favorite